Literature DB >> 12555938

Introduction of a ketogenic diet in young infants.

J Klepper1, B Leiendecker, R Bredahl, S Athanassopoulos, F Heinen, E Gertsen, A Flörcken, A Metz, T Voit.   

Abstract

The ketogenic diet is a rational treatment for pyruvate dehydrogenase complex deficiency (McKusick 312170) and GLUT1 deficiency syndrome (McKusick 138140). An increasing number of patients are diagnosed in early infancy, but few data are available on the introduction of a ketogenic diet in this age group. GLUT1 deficiency syndrome was suspected in four infants presenting with seizures and unexplained hypoglycorrhachia. A ketogenic diet was introduced at 6-28 weeks of age. Ketosis was initiated by fasting, monitored by bedside blood glucose and 3-hydroxybutyrate determinations, and was maintained successfully using supplemented carbohydrate-free infant formula and emulgated triglycerides. All patients developed ketosis within 24 h. 3-Hydroxybutyrate concentrations available at the bedside correlated inversely with the base excess. At glucose levels < or = 40 mg/dl patients remained asymptomatic in the presence of ketones. The ketogenic formula was tolerated well, parental compliance was good, and all patients remained seizure-free on the diet. GLUT1 deficiency was confirmed in two patients; the diet was discontinued in the other two patients. In one infant, failure to thrive on medium-chain triglycerides was effectively reversed using long-chain triglycerides. Urine dipstick analyses failed to detect ketosis in another infant. Adverse effects of the diet were limited to renal stones in one patient. The ketogenic diet can be introduced and maintained successfully in young infants using long-chain fat emulsion. Monitoring 3-hydroxybutyrate at the bedside was useful for metabolic control and superior to urine dipstick analysis. Seizure control was effective and adverse effects were limited, but evaluation of the long-term effects of the ketogenic diet in this age group must await ongoing studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555938     DOI: 10.1023/a:1021238900470

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Defective glucose transport across brain tissue barriers: a newly recognized neurological syndrome.

Authors:  J Klepper; D Wang; J Fischbarg; J C Vera; I T Jarjour; K R O'Driscoll; D C De Vivo
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization.

Authors:  W M Pardridge; R J Boado; C R Farrell
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

Review 3.  The ketogenic diet revisited: back to the future.

Authors:  D R Nordli; D C De Vivo
Journal:  Epilepsia       Date:  1997-07       Impact factor: 5.864

4.  GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier.

Authors:  G Seidner; M G Alvarez; J I Yeh; K R O'Driscoll; J Klepper; T S Stump; D Wang; N B Spinner; M J Birnbaum; D C De Vivo
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

5.  The ketogenic diet: Fa(c)t or fiction.

Authors:  J W Wheless
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

6.  Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome.

Authors:  D Wang; P Kranz-Eble; D C De Vivo
Journal:  Hum Mutat       Date:  2000-09       Impact factor: 4.878

Review 7.  Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review.

Authors:  Jörg Klepper; Thomas Voit
Journal:  Eur J Pediatr       Date:  2002-04-16       Impact factor: 3.183

Review 8.  The ketogenic diet: 1997.

Authors:  T D Swink; E P Vining; J M Freeman
Journal:  Adv Pediatr       Date:  1997

9.  Autosomal dominant glut-1 deficiency syndrome and familial epilepsy.

Authors:  K Brockmann; D Wang; C G Korenke; A von Moers; Y Y Ho; J M Pascual; K Kuang; H Yang; L Ma; P Kranz-Eble; J Fischbarg; F Hanefeld; D C De Vivo
Journal:  Ann Neurol       Date:  2001-10       Impact factor: 10.422

10.  A multicenter study of the efficacy of the ketogenic diet.

Authors:  E P Vining; J M Freeman; K Ballaban-Gil; C S Camfield; P R Camfield; G L Holmes; S Shinnar; R Shuman; E Trevathan; J W Wheless
Journal:  Arch Neurol       Date:  1998-11
View more
  14 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

2.  A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: case studies for rare diseases and COVID-19.

Authors:  Alzbeta Tuerkova; Barbara Zdrazil
Journal:  J Cheminform       Date:  2020-11-25       Impact factor: 5.514

Review 3.  Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease.

Authors:  Katharina Danhauser; Jan A M Smeitink; Peter Freisinger; Wolfgang Sperl; Hemmen Sabir; Berit Hadzik; Ertan Mayatepek; Eva Morava; Felix Distelmaier
Journal:  J Inherit Metab Dis       Date:  2015-02-17       Impact factor: 4.982

4.  Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.

Authors:  Juan M Pascual; Peiying Liu; Deng Mao; Dorothy I Kelly; Ana Hernandez; Min Sheng; Levi B Good; Qian Ma; Isaac Marin-Valencia; Xuchen Zhang; Jason Y Park; Linda S Hynan; Peter Stavinoha; Charles R Roe; Hanzhang Lu
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

5.  A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: case studies for rare diseases and COVID-19.

Authors:  Alzbeta Tuerkova; Barbara Zdrazil
Journal:  J Cheminform       Date:  2020-11-25       Impact factor: 5.514

6.  A family with pyruvate dehydrogenase complex deficiency due to a novel C>T substitution at nucleotide position 407 in exon 4 of the X-linked Epsilon1alpha gene.

Authors:  Már Tulinius; Niklas Darin; Lars-Martin Wiklund; Eva Holmberg; Jan Erik Eriksson; Willy Lissens; Linda De Meirleir; Elisabeth Holme
Journal:  Eur J Pediatr       Date:  2004-11-19       Impact factor: 3.183

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 8.  Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes.

Authors:  Preeti Kanikarla-Marie; Sushil K Jain
Journal:  Free Radic Biol Med       Date:  2016-03-29       Impact factor: 7.376

Review 9.  Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.

Authors:  Juan M Pascual; Gabriel M Ronen
Journal:  Pediatr Neurol       Date:  2015-08-10       Impact factor: 3.372

Review 10.  Ketone body metabolism and its defects.

Authors:  Toshiyuki Fukao; Grant Mitchell; Jörn Oliver Sass; Tomohiro Hori; Kenji Orii; Yuka Aoyama
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.